We are live on ! Find out more
RZLT icon

Rezolute

3.92 USD
-0.28
6.67%
At close Updated Nov 20, 4:00 PM EST
Pre-market
After hours
3.95
+0.03
0.77%
1 day
-6.67%
5 days
7.4%
1 month
5.95%
3 months
-15.88%
6 months
21.74%
Year to date
80.65%
1 year
-59.38%
5 years
-27.41%
10 years
-80.88%
 

About: Rezolute Inc is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its main clinical asset, Ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism. The company has a single reportable segment, which includes all of its activities as a clinical-stage biopharmaceutical company.

Employees: 58

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 9.1%
Neutral 90.9%
Negative 0%
Positive
Benzinga
8 days ago
Rezolute Raises $100 Million, Advances Ersodetug Toward Commercialization
Rezolute Inc. (NASDAQ:RZLT) on Friday achieved the primary efficacy endpoint in its ongoing open-label Phase 3 upLIFT study of ersodetug for tumor hyperinsulinism while pricing an underwritten offering expected to generate roughly $100 million in gross proceeds.
Rezolute Raises $100 Million, Advances Ersodetug Toward Commercialization
Neutral
GlobeNewsWire
9 days ago
Rezolute Announces Pricing of Approximately $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Transaction led by Frazier Life Sciences with participation from new and existing funds REDWOOD CITY, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or the Company), a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today announced the pricing of an underwritten offering of 22,040,976 shares of its common stock at an offering price of $3.87 per share, and to certain investors in lieu of common stock, pre-funded warrants to purchase up to 3,800,000 shares of common stock at an offering price of $3.869 per pre-funded warrant, which represents the per share offering price for the common stock, less the $0.001 per share exercise price for each such pre-funded warrant.
Rezolute Announces Pricing of Approximately $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Neutral
GlobeNewsWire
9 days ago
Rezolute Announces Positive Results from the Phase 3 upLIFT Study in Tumor Hyperinsulinism
Primary efficacy endpoint achieved based on preliminary results from a November 5th data evaluation
Rezolute Announces Positive Results from the Phase 3 upLIFT Study in Tumor Hyperinsulinism
Neutral
GlobeNewsWire
16 days ago
Rezolute Reports First Quarter Fiscal 2027 Financial Results and Provides Business Update
REDWOOD CITY, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or the Company), a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today reported financial results and provided a business update for the first quarter ended September 30, 2026.
Rezolute Reports First Quarter Fiscal 2027 Financial Results and Provides Business Update
Neutral
GlobeNewsWire
19 days ago
Rezolute to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or Company), a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today announced that management will participate in the following investor conferences: Event: Guggenheim 3rd Annual Healthcare Innovation Conference Date: November 9-11, 2026 Fireside Date/Time: Monday, November 9th at 9:00am ET Event: Jefferies London Healthcare Conference Date: November 16-19, 2026 Fireside Date/Time: Thursday, November 19th at 1:00pm GMT Management will be participating in one-on-one investor meetings throughout the conferences.
Rezolute to Participate in Upcoming Investor Conferences
Neutral
GlobeNewsWire
1 month ago
Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
Topline results expected mid-December 2026 REDWOOD CITY, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or Company), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today announced that the open-label Phase 3 study of ersodetug in tumor HI (upLIFT) is now fully enrolled and topline data are expected mid-December 2026.
Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
Neutral
GlobeNewsWire
1 month ago
Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism
The Agency reiterated its commitment to addressing the unmet need for treatment of congenital and tumor-related hyperinsulinism and to serving these patient communities
Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism
Neutral
Benzinga
1 month ago
5 Stock Picks Last Week From Wall Street's Most Accurate Analysts
U.S. stocks settled higher on Friday, with the Dow Jones index recording sharp gains during the session as crude oil retreated on hopes for an Iran-brokered reopening of the Strait of Hormuz.
5 Stock Picks Last Week From Wall Street's Most Accurate Analysts
Neutral
GlobeNewsWire
1 month ago
Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update
REDWOOD CITY, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today reported financial results and provided a business update for the fourth quarter and full fiscal year ended June 30, 2026.
Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update
Neutral
GlobeNewsWire
2 months ago
Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
Data from the Phase 3 sunRIZE study remains under review by FDA  The OLE Phase of the study is ongoing, with a high participation rate and several indicators of improved glycemic control, including a notable reduction in the use of background standard of care therapies Enrollment continues in the Phase 3 upLIFT study in tumor HI and the Company remains on track to report topline results before the end of 2026 REDWOOD CITY, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (“HI”), today provided an update on the status of the ongoing U.S. Food and Drug Administration (“FDA” or “Agency”) review of data from the Company's Phase 3 sunRIZE study of ersodetug for the treatment of hypoglycemia due to congenital HI.
Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
Price charts implemented using Lightweight Charts™